1. In Vivo

Biopharma Dealmaking Quarterly Statistics, Q2 2014

A look at financing, M&A, and alliance activity April–June 2014

Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.

Biopharma financing declined 36% in the second quarter of 2014 to $7.2 billion, compared with Q1’s $9.8 billion. (See Exhibit 1.) Just under 30 fewer deals were done in Q2 than in Q1 (131 vs. 159), but the first half of 2014’s $16.9 billion in dollar volume has out-paced H1 2013’s $15.6 billion, which even included two large outliers: Valeant Pharmaceuticals International Inc.’s simultaneous $2.3 billion FOPO [See Deal] and $3.2 billion debt offering [See Deal] to support its Bausch & Lomb Inc. acquisition. [See Deal] If those two Valeant deals are excluded, the financing environment in the first half of 2014 has far exceeded that of last year’s.

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.